相关临床试验
143
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1946
进行中（未招募）
11
7.7%
已完成
95
66.4%
Enrolling By Invitation
1
0.7%
尚未招募
4
2.8%
招募中
15
10.5%
终止
3
2.1%
Unknown
12
8.4%
撤回
2
1.4%
暂无批准数据
- Cure Parkinson's has announced £1 million in funding for SLEIPNIR, a new multi-arm clinical trial platform in Norway that will test up to three potentially disease-modifying Parkinson's treatments simultaneously against one placebo group. - The platform, led by Professor Charalampos Tzoulis at Haukeland University Hospital and the University of Bergen, will assess drug brain penetrance and target interaction through blood and cerebrospinal fluid analysis. - SLEIPNIR aims to address the critical challenge of determining whether treatments reach the brain effectively, as many late-stage trials have failed due to insufficient brain penetrance. - The platform is designed to reduce the risk of larger clinical trial failures by evaluating multiple drugs in a smaller, shorter timeframe before advancing promising treatments to late-stage platforms like EJS ACT-PD.
- Researchers have discovered that mitochondria act as a crucial reservoir for NAD+, a molecule essential for cellular energy and function, maintaining cellular health. - The study reveals that mitochondrial dysfunction and depletion of NAD+ are linked to aging and age-related disorders like neurodegenerative diseases. - Supplementation strategies to increase NAD+ levels have shown promising results in initial clinical trials, suggesting a potential therapeutic avenue for aging-related conditions. - Using advanced techniques, the study elucidated the molecular mechanisms by which mitochondria counteract cellular NAD+ decline, highlighting the importance of basic research in identifying targets for aging and disease.
